BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1388041)

  • 1. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
    Bloomer JC; Woods FR; Haddock RE; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1992 May; 33(5):521-3. PubMed ID: 1388041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
    Wang RW; Liu L; Cheng H
    Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
    Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
    Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
    Sanwald P; David M; Dow J
    Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol.
    Pepper JM; Lennard MS; Tucker GT; Woods HF
    Pharmacogenetics; 1991 Nov; 1(2):119-22. PubMed ID: 1844870
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
    Feifel N; Kucher K; Fuchs L; Jedrychowski M; Schmidt E; Antonin KH; Bieck PR; Gleiter CH
    Eur J Clin Pharmacol; 1993; 45(3):265-9. PubMed ID: 8276052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes.
    Narimatsu S; Kariya S; Isozaki S; Ohmori S; Kitada M; Hosokawa S; Masubuchi Y; Suzuki T
    Biochem Biophys Res Commun; 1993 Jun; 193(3):1262-8. PubMed ID: 8323546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
    J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
    Blankson EA; Ellis SW; Lennard MS; Tucker GT; Rogers K
    Biochem Pharmacol; 1991 Dec; 42 Suppl():S209-12. PubMed ID: 1768279
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    Tyndale RF; Kalow W; Inaba T
    Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine.
    Yumibe N; Huie K; Chen KJ; Clement RP; Cayen MN
    Int Arch Allergy Immunol; 1995; 107(1-3):420. PubMed ID: 7613198
    [No Abstract]   [Full Text] [Related]  

  • 17. Paroxetine: lack of effect on hepatic drug metabolizing enzymes.
    Haddock RE; Jackson D; Woods FR
    Acta Psychiatr Scand Suppl; 1989; 350():93-4. PubMed ID: 2530800
    [No Abstract]   [Full Text] [Related]  

  • 18. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
    Caraco Y; Tateishi T; Guengerich FP; Wood AJ
    Drug Metab Dispos; 1996 Jul; 24(7):761-4. PubMed ID: 8818573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
    Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
    Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.
    Yasui-Furukori N; Hidestrand M; Spina E; Facciolá G; Scordo MG; Tybring G
    Drug Metab Dispos; 2001 Oct; 29(10):1263-8. PubMed ID: 11560868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.